The “C” of Viral Hepatitis in Children

Michael R. Narkewicz; Roniel Cabrera; Regino P. González-Peralta

doi:10.1055/s-2007-985074

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2007; 27(3): 295-311
DOI: 10.1055/s-2007-985074

The “C” of Viral Hepatitis in Children

Michael R. Narkewicz¹ , Roniel Cabrera² , Regino P. González-Peralta³

¹Pediatric Liver Center, Section of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Colorado School of Medicine and The Children's Hospital, Denver, Colorado
²Section of Hepatobiliary Diseases, Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, University of Florida College of Medicine, Gainesville, Florida
³Pediatric Hepatology and Liver Transplantation, Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida

Abstract

ABSTRACT

Chronic hepatitis C virus (HCV) infection is a major global health problem. The incidence of transfusion-related HCV infection has markedly decreased, and perinatal transmission has become the most important route of viral spread in children. Perinatally acquired HCV infection is generally a benign condition, but severe liver disease can occur. Little is known about the risk factors for the progression of liver disease in children, and few well-designed pediatric clinical trials have been conducted. Therefore, the decision to treat (or not) children with this viral pathogen is currently a contentious endeavor. Herein, we describe the virus and its life cycle and summarize our current understanding of the epidemiology and natural history of perinatally acquired infection and review current and future therapy of HCV infection in children.

KEYWORDS

Hepatitis C virus - children - transmission - treatment

Full Text

References

REFERENCES

1 Shepard C W, Finelli L, Alter M J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5 558-567
2 World Health Organization . Hepatitis C. Wkly Epidemiol Rec. 1997; 72 65-72
3 Wong J B, McQuillan G M, McHutchison J G, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000; 90 1562-1569
4 Jhaveri R, Grant W, Kauf T L, McHutchison J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr. 2006; 148 353-358
5 Donahue J G, Munoz A, Ness P M et al.. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992; 327 369-373
6 Robertson B, Myers G, Howard C et al.. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch Virol. 1998; 143 2493-2503
7 Branch A D, Stump D D, Gutierrez J A, Eng F, Walewski J L. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin Liver Dis. 2005; 25 105-117
8 Thomson M, Liang T J. Molecular biology of hepatitis C virus. In: Liang TJ, Hoofnagle JH Hepatitis C. San Diego, CA; Academic Press 2000: 1-23
9 Smith R M, Wu G Y. Molecular virology of hepatitis B and C. In: Koff RS, Wu GY Chronic Viral Hepatitis: Diagnosis and Therapeutics. Totowa, NJ; Humana Press 2002: 1-24
10 Tellinghuisen T L, Rice C M. Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol. 2002; 5 419-427
11 Martell M, Esteban J I, Quer J et al.. Hepatitis C virus circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992; 66 3225-3229
12 Moribe T, Hayashi N, Kanasawa Y et al.. Hepatitis C viral complexity detected by single strand conformational polymorphism and response to interferon therapy. Gastroenterology. 1995; 108 789-795
13 González-Peralta R P, Qian K, She J Y et al.. Clinical implications of viral quasispecies in chronic hepatitis C. J Med Virol. 1996; 49 242-247
14 González-Peralta R P, Liu W, Davis G L et al.. Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin. J Viral Hepat. 1997; 4 99-106
15 Canobio S, Guilbert C M, Troesch M et al.. Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1. J Clin Microbiol. 2004; 42 4365-4369
16 Ishii T, Ohto H, Takeuchi C et al.. Evolution in the hypervariable region of the hepatitis C virus in two infants infected by mother-to-infant transmission. Pediatr Int. 2005; 47 278-285
17 Farci P, Quinti I, Farci S et al.. Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci USA. 2006; 103 8475-8480
18 Caudai C, Battiata M, Riccardi M P et al.. Vertical transmission of the hepatitis C virus to infants of anti-human immunodeficiency virus-negative mothers: molecular evolution of hypervariable region 1 in prenatal and perinatal or postnatal infections. J Clin Microbiol. 2003; 41 3955-3959
19 Lau J YN, Davis G L, Prescott L E et al.. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med. 1996; 124 868-876
20 Jara P, Resti M, Hierro L et al.. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis. 2003; 36 275-280
21 Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology. 2002; 36 1280-1284
22 González-Peralta R P, Kelly D A, Haber B for the International Pediatric Hepatitis C Therapy Group et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. 2005; 42 1010-1018
23 Jacobson K R, Murray K, Zellos A, Schwarz K B. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2002; 34 52-58
24 Jonas M M, Ott M J, Nelson S P et al.. Interferon-alpha treatment of chronic hepatitis C virus infection in children. Pediatr Infect Dis J. 1998; 17 241-246
25 Matsuoka S, Tatara K, Hayabuchi Y et al.. Serologic, virologic, and histologic characteristics of chronic phase hepatitis C virus disease in children infected by transfusion. Pediatrics. 1994; 94 919-922
26 Garcia-Monzon C, Jara P, Fernandez-Bermejo M et al.. Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients. Hepatology. 1998; 28 1696-1701
27 Brass V, Moradpour D, Blum H E. Molecular virology of hepatitis C virus: 2006 update. Int J Med Sci. 2006; 3 29-34
28 Lindenbach B D, Rice C M. Unraveling hepatitis C virus replication from genome to function. Nature. 2005; 436 933-938
29 Evans M J, von Hahn T, Tscherne D M et al.. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 2007; 446 801-805
30 Cocquerel L, Voisset C, Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol. 2006; 87 1075-1084
31 Spahn C M, Kieft J S, Grassucci R A et al.. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40S ribosomal subunit. Science. 2001; 291 1959-1962
32 Gosert R, Egger D, Lohmann V et al.. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol. 2003; 77 5487-5492
33 Quinkert D, Bartenschlager R, Lohmann V. Quantitative analysis of the hepatitis C virus replication complex. J Virol. 2005; 79 13594-13605
34 Sakai A, Claire M S, Faulk K et al.. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci USA. 2003; 100 11646-11651
35 Yi M, Ma Y, Yates J, Lemon S M. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol. 2007; 81 629-638
36 Haqshenas G, Mackenzie J M, Dong X, Gowans E J. Hepatitis C virus p7 protein is localized in the endoplasmic reticulum when it is encoded by a replication-competent genome. J Gen Virol. 2007; 88 134-142
37 Neumann A U, Lam N P, Dahari H et al.. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science. 1998; 282 103-107
38 Alter M J, Kruszon-Moran D, Nainan O V et al.. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341 556-562
39 Bortolotti F, Jorio R, Resti M et al.. Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. J Hepatol. 2007; 46 783-790
40 Roberts E A, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology. 2002; 36(suppl 1) S106-S113
41 European Paediatric Hepatitis C Virus Network . A significant sex-but not elective cesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis. 2005; 192 1872-1879
42 Dore G J, Kaldor J M, McCaughan G W. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ. 1997; 315 333-337
43 Pappalardo B L. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol. 2003; 32 727-734
44 Gibb D M, Goodall R L, Dunn D T et al.. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet. 2000; 356 904-907
45 Ferrero S, Lungaro P, Bruzzone B M, Gotta C, Bentivoglio G, Ragni N. Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990-2000). Acta Obstet Gynecol Scand. 2003; 82 229-234
46 Giacchino R, Tasso L, Timitilli A et al.. Vertical transmission of hepatitis C virus infection: usefulness of viremia detection in HIV-seronegative hepatitis C virus-seropositive mothers. J Pediatr. 1998; 132 167-169
47 Okamoto M, Nagata I, Murakami J et al.. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. J Infect Dis. 2000; 182 1511-1514
48 Resti M, Azzari C, Mannelli F et al.. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ. 1998; 317 437-441
49 Steininger C, Kundi M, Jatzko G, Kiss H, Lischka A, Holzmann H. Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis. 2003; 187 345-351
50 Tajiri H, Miyoshi Y, Funada S et al.. Prospective study of mother-to-infant transmission of hepatitis C virus. Pediatr Infect Dis J. 2001; 20 10-14
51 Zanetti A R, Tanzi E, Romano L et al.. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology. 1998; 41 208-212
52 Azzari C, Resti M, Moriondo M, Ferrari R, Lionetti P, Vierucci A. Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. Blood. 2000; 96 2045-2048
53 Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology. 2000; 31 751-755
54 Paccagnini S, Principi N, Massironi E et al.. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J. 1995; 14 195-199
55 Resti M, Azzari C, Galli L et al.. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J Infect Dis. 2002; 185 567-572
56 European Paediatric Hepatitis C Virus Network . Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. BJOG. 2001; 108 371-377
57 McIntyre P G, Tosh K, McGuire W. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. Cochrane Database Syst Rev. 2006; (4) CD005546
58 Pembrey L, Newell M L, Tovo P A. The management of HCV infected pregnant women and their children. European Paediatric HCV Network. J Hepatol. 2005; 43 515-525
59 Davies G, Wilson R D, Desilets V et al.. Amniocentesis and women with hepatitis B, hepatitis C, or human immunodeficiency virus. J Obstet Gynaecol Can. 2003; 25 145-152
60 Mok J, Pembrey L, Tovo P A, Newell M L. When does mother to child transmission of hepatitis C virus occur?. Arch Dis Child Fetal Neonatal Ed. 2005; 90 F156-F160
61 Kumar R M, Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. J Hepatol. 1998; 29 191-197
62 Lin H H, Kao J H, Hsu H Y et al.. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr. 1995; 126 589-591
63 Della Bella S, Riva A, Tanzi E et al.. Hepatitis C virus-specific reactivity of CD4 + -lymphocytes in children born from HCV-infected women. J Hepatol. 2005; 43 394-402
64 Martinetti M, Pacati I, Daielli C, Salvaneschi L, Maccabruni A. Critical role of Val/Gly86 HLA-DRB dimorphism in the neonatal resistance or susceptibility to maternal hepatitis C virus infection. Pediatr Infect Dis J. 1997; 16 1001-1002
65 Mast E E, Hwang L Y, Seto D S et al.. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005; 192 1880-1889
66 Polywka S, Pembrey L, Tovo P A, Newell M L. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol. 2006; 78 305-310
67 Resti M, Jara P, Hierro L et al.. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol. 2003; 70 373-377
68 Jara P, Resti M, Hierro L et al.. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis. 2003; 36 275-280
69 European Paediatric Hepatitis C Virus Network . Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005; 41 45-51
70 Casiraghi M A, De Paschale M, Romano L et al.. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology. 2004; 39 90-96
71 McDiarmid S V, Anand R. SPLIT Research Group . Studies of pediatric liver transplantation (SPLIT): a summary of the 2003 annual report. Clin Transpl. 2003; 119-130
72 Rumbo C, Fawaz R L, Emre S H et al.. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr. 2006; 43 209-216
73 González-Peralta R P, Langham M R, Mohan P, Colombani P M, Alford M K, Schwarz K B. Hepatocellular carcinoma in two adolescents with chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2003; 37 380 (Abstract)
74 Iorio R, Giannattasio A, Sepe A, Terracciano L M, Vecchione R, Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis. 2005; 41 1431-1437
75 Shneider B L, González-Peralta R P, Roberts E A. Controversies in the management of pediatric liver diseases: hepatitis B, C and NAFLD. Hepatology. 2006; 44 1344-1354
76 Feld J J, Hoofnagle J H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005; 436 967-972
77 de Veer M J, Holko M, Frevel M et al.. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol. 2001; 69 912-920
78 Sen G C. Viruses and interferons. Annu Rev Microbiol. 2001; 55 255-281
79 Shindo M, Di Bisceglie A M, Cheung L et al.. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 1991; 115 700-704
80 Davis G L. Treatment of acute and chronic hepatitis C. Clin Liver Dis. 1997; 1 615-630
81 Jacobson K R, Murray K, Zellos A, Schwarz K B. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2002; 34 52-58
82 Davis G L, Esteban-Mur R, Rustgi V et al.. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339 1493-1499
83 McHutchison J G, Gordon S C, Schiff E R et al.. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339 1485-1492
84 Christensson B, Wiebe T, Akesson A, Widell A. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis. 2000; 30 585-586
85 Lackner H, Moser A, Deutsch J et al.. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics. 2000; 106 E53-E56
86 Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology. 2002; 36 1280-1284
87 González-Peralta R P, Glue P, Hodik M, Davis G L, Lau J YN. Single-dose pharmacokinetics of interferon alfa2b in children with chronic hepatitis C. Hepatology. 1999; 30 264A
88 Manns M P, McHutchison J G, Gordon S C et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358 958-965
89 Fried M W, Shiffman M L, Reddy K R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347 975-982
90 Schwarz K B, Mohan P, Narkewicz M R et al.. The safety, efficacy, and pharmacokinetics of peginterferon alfa-2b (40kD) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2006; 43 499-505
91 Wirth S, Pieper-Boustani H, Lang T et al.. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology. 2005; 41 1013-1018
92 Davis G L, Wong J B, McHutchison J G, Manns M P, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003; 38 645-652
93 Polifka J E, Friedman J M. Developmental toxicity of ribavirin/IFalpha combination therapy: is the label more dangerous than the drugs?. Birth Defects Res A Clin Mol Teratol. 2003; 67 8-12
94 Barlow C F, Priebe C J, Mulliken J B et al.. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998; 132 527-530
95 Murray K F, Barton B, González-Peralta R P for the PEDS-C Clinical Research Network et al. Development of a multi-center, randomized controlled trial for children with chronic hepatitis C (PEDS-C). J Pediatr Gastroenterol Nutr. 2005; 41 524 (Abstract)
96 U.S. Code of Federal Regulations .Title 21, Food and Drugs: 314.55 and 601.27.
97 Balan V, Nelson D R, Sulkowski M S et al.. Phase I/II study evaluating escalating subcutaneous doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther. 2006; 11 35-45
98 Bain V G, Kaita K D, Yoshida E M et al.. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol. 2006; 44 671-678
99 Gish R G. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006; 57 8-13
100 Gish R G, Arora S, Reddy K R et al.. Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol. 2007; 47 51-59
101 Benhamou Y, Pockros P, Rodriquez-Torres M et al.. The safety and efficacy of viramidine plus pegylated interferon alfa-2b versus ribavirin plus pegylated interferon alfa-2b in therapy-naïve patients infected with HCV: phase 3 results. J Hepatol. 2006; 44(suppl 2) S273
102 McHutchison J G, Shiffman M L, Cheung R C et al.. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. Antivir Ther. 2005; 10 635-643
103 Pockros P J, Pessoa M G, Diago M et al.. Combination of levovirin and peginterferon alfa-2a fails to generate virological response comparable to ribavirin and peginterferon alfa-2a in patients with chronic hepatitis C. Hepatology. 2004; 40(suppl) 391A
104 Welbourn S, Green R, Gamache I et al.. Hepatitis C virus NS2/3 processing is required for NS3 stability and viral RNA replication. J Biol Chem. 2005; 280 29604-29611
105 Grakoui A, McCourt D W, Wychowski C, Feinstone S M, Rice C M. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol. 1993; 67 2832-2843
106 Foy E, Li K, Wang C et al.. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science. 2003; 300 1145-1148
107 Lemon S M, Yi M, Li K. “Strong reasons make strong actions”-the antiviral efficacy of NS3/4A protease inhibitors. Hepatology. 2005; 41 671-674
108 Hinrichsen H, Benhamou Y, Wedemeyer H et al.. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology. 2004; 127 1347-1355
109 Reesink H W, Zeuzem S, Weegink C J et al.. Final results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology. 2005; 42 234A
110 Reesink H W, Zeuzem S, Weegink C J et al.. Initial results of a 14-day study of the hepatitis C virus inhibitor VX-950, in combination with peginterferon-alfa 2a. J Hepatol. 2006; 44(suppl 2) S272
111 Lawitz E, Rodriguez-Torres M, Muir A et al.. 28 days of the hepatitis C protease inhibitor VX-950, in combination with peg-interferon-alfa-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Gastroenterology. 2006; 130(suppl 2) A686
112 Zeuzem S, Sarrazin C, Rouzier R et al.. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (peg-IFN-α). Hepatology. 2005; 42 233A
113 Zeuzem S, Sarrazin C, Wagner F et al.. Combination therapy with the HCV protease inhibitor, SCH 503034, plus PEG-Intron in hepatitis C genotype-1 PEG-Intron non-responders: phase Ib results. Hepatology. 2005; 42 276A
114 Gale M, Foy E. Evasion of intracellular host defense by hepatitis C virus. Nat Med. 2005; 436 939-945
115 Zeuzem S, Sarrazin C, Rouzier R et al.. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (peg-IFN-α). Hepatology. 2005; 42 233A
116 Kieffer T, Sarrazin C, Miller J et al.. Combination of telaprevir (VX-950) and PEG-IFN-alfa suppressed both wild-type virus and resistance variants in HCV genotype 1-infected patients in a 14-day phase 1B study. Hepatology. 2006; 44 222A
117 Kieffer T, Sarrazin C, Bartels D et al.. Wild-type HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCV. J Hepatol. 2006; 44(suppl 2) S7
118 O'Brien C, Godofsky E, Roriguez-Torres M et al.. Randomized trial of valopicitabine (NM283) alone or with PEG-interferon vs. retreatment with PEG-interferon plus ribavirin (PEGIFN/RBV) in hepatitis C patients with previous non-response to PEGIFN.RBV: first interim results. Hepatology. 2005; 42 232A
119 Dieterich D, Lawitz E, Nguyen T et al.. Early clearance of HCV RNA with valopicitabine (NM283) plus peg-interferon in treatment-naïve patients with HCV-1 infection: first results from a phase IIb trial. J Hepatol. 2006; 44(suppl 2) S271-S272
120 Roberts S, Cooksley G, Dore G et al.. Results of a phase 1B multiple dose study of R1626 a novel nucleoside analog targeting HCV polymerase in chronic HCV genotype 1 patients. Hepatology. 2006; 44 692A
121 Chandra P, Raible D, Harper D, Speth J, Villano S, Bichier G. Antiviral activity of the non-nucleoside polymerase inhibitor HCV-796 in patients with chronic hepatitis C virus: preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. Gastroenterology. 2006; 130(suppl 2) A748

Regino P González-PeraltaM.D.

Pediatric Gastroenterology, Hepatology, and Nutrition

P.O. Box 100296, University of Florida College of Medicine, Gainesville, FL 32610